Letrozole

Generic Name: Letrozole

Brand Names: Femara, Kisqali Femara Co-pack

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₁N_₅

CAS Number: 112809-51-5

Unique Ingredient Identifier: 7LKK855W8I

Background: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication: Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.

Associated Conditions: Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer

Associated Therapies: -

Clinical Trials

The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)

Phase 3

Completed

Conditions: Polycystic Ovarian Syndrome

Interventions: Drug: Letrozole

First Posted Date: 2012-04-13

Last Posted Date: 2012-06-14

Lead Sponsor: Nik Hazlina

Target Recruit Count: 150

Registration Number: NCT01577017

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen,
Drug: Exemestane
Drug: Anastrozole
Drug: Letrozole

First Posted Date: 2012-03-14

Last Posted Date: 2013-06-04

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 29

Registration Number: NCT01553903

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms
Endocrine Breast Diseases
Neoplasm Metastasis

Interventions: Drug: letrozole
Drug: lapatinib
Drug: everolimus

First Posted Date: 2011-12-26

Last Posted Date: 2022-02-11

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 7

Registration Number: NCT01499160

Locations: 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States

Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy

Not Applicable

Conditions: Complete Abortion

Interventions: Drug: mifepristone
Drug: Letrozole
Drug: Misoprostol

First Posted Date: 2011-11-21

Last Posted Date: 2011-11-21

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 50

Registration Number: NCT01475318

Locations: 🇭🇰
Joyce Chai, Hong Kong, Hong Kong

Reproductive Hormonal Alterations in Obesity

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Cetrorelix
Drug: Gonadorelin-GnRH
Drug: Recombinant LH
Drug: Letrozole

First Posted Date: 2011-10-24

Last Posted Date: 2017-01-12

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 62

Registration Number: NCT01457703

Locations: 🇺🇸
Clinical Translational Research Center, Aurora, Colorado, United States

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Procedure: MRI
Procedure: conventional surgery

First Posted Date: 2011-09-23

Last Posted Date: 2018-03-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 108

Registration Number: NCT01439711

Locations: 🇺🇸
Southern Ohio Medical Center, Portsmouth, Ohio, United States
🇺🇸
Missouri Baptist Medical Center, Saint Louis, Missouri, United States
🇺🇸
Bay Area Tumor Institute, Oakland, California, United States

and more 29 locations

Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)

Not Applicable

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Letrozole
Drug: Chinese herbal medicine granules or Chinese herbal medicine granules placebo

First Posted Date: 2011-09-09

Last Posted Date: 2013-11-05

Lead Sponsor: Heilongjiang University of Chinese Medicine

Target Recruit Count: 420

Registration Number: NCT01431352

Locations: 🇨🇳
Guangzhou Medical School First Affiliated Hospital, Guangzhou, Guangdong, China
🇨🇳
Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China
🇨🇳
Daqing Longnan hospital, Daqing, Heilongjiang, China

and more 15 locations